Brief: Opsens Announces FDA Clearance For The Savvywire™ For Use In Transcatheter Aortic Valve Replacement (TAVR) Procedures
15/09/2022 12:03
Sept 15 (Reuters) - Opsens Inc OPS.TO :
* OPSENS ANNOUNCES FDA CLEARANCE FOR THE SAVVYWIRE™ FOR USE
IN
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PROCEDURES
Source text for Eikon: ID:nCNWKwkf2a
Further company coverage: OPS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opsens
See all newsBrief: Haemonetics Corporation Completes Acquisition Of Opsens
Brief: Opsens Receives Final Order For Arrangement With Haemonetics
Brief: Opsens Obtains Regulatory Clearance Of Arrangement In US And Canada
Brief: OpSens- Independent Proxy Advisory Firm ISS Recommends Shareholders Vote "For"
Brief: Opsens Announces Positive Clinical Results From Safe-Tavi Study With Savvywire In Europe